Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2-Reference-Cited by-同舟云学术

Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2

Published:2010-03 Issue:2 Volume:2 Page:199-208
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Mamluk Roni,Carvajal Irvith M.,Morse Brent A.,Wong Henry K,Abramowitz Janette,Aslanian Sharon,Lim Ai-Ching,Gokemeijer Jochem,Storek Michael J.,Lee Joonsoo,Gosselin Michael,Wright Martin C.,Camphausen Ray T.,Wang Jack,Chen Yan,Miller Kathy,Sanders Kerry,Short Sarah,Sperinde Jeff,Prasad Gargi,Williams Stephen,Kerbel Robert S.,Ebos John,Mutsaers Anthony,Mendlein John D.,Harris Alan S.,Furfine Eric S.

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/mabs.2.2.11304

Reference42 articles.

1. Tumor Angiogenesis

2. VEGFR3: A New Target for Antiangiogenesis Therapy?

3. Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor

4. Vascular endothelial growth factor (VEGF) and its receptors

5. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving the pharmacokinetics, biodistribution and plasma stability of monobodies;Frontiers in Pharmacology;2024-04-04

2. Identification of Inhibitors of the Disease-Associated Protein Phosphatase Scp1 Using Antibody Mimetic Molecules;International Journal of Molecular Sciences;2024-03-27

3. Targeted Glioma Therapy—Clinical Trials and Future Directions;Pharmaceutics;2024-01-11

4. Sequence-developability mapping of affibody and fibronectin paratopes via library-scale variant characterization;Protein Engineering, Design and Selection;2024

5. Non-immunoglobulin synthetic binding proteins for oncology;Биохимия;2023-12-15